Nkarta, Inc. (NASDAQ:NKTX – Get Rating) has been given a consensus rating of "Moderate Buy" by the nine ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $28.57.
Several brokerages recently weighed in on NKTX. Canaccord Genuity Group began coverage on shares of Nkarta in a research note on Monday, October 10th. They issued a "buy" rating and a $25.00 target price for the company. Oppenheimer downgraded shares of Nkarta from an "outperform" rating to a "market perform" rating in a research note on Thursday, December 22nd. Mizuho dropped their price objective on shares of Nkarta from $81.00 to $26.00 and set a "buy" rating for the company in a research note on Wednesday, November 16th. Finally, Canaccord Genuity Group began coverage on shares of Nkarta in a research note on Monday, October 10th. They set a "buy" rating and a $25.00 price objective for the company.
Get Nkarta alerts:Nkarta Trading Down 4.7 %
Shares of NKTX stock opened at $5.07 on Tuesday. The firm has a 50-day moving average price of $7.07 and a 200 day moving average price of $11.43. Nkarta has a twelve month low of $4.83 and a twelve month high of $20.35. The company has a market capitalization of $247.49 million, a price-to-earnings ratio of -1.90 and a beta of 0.17.
Nkarta (NASDAQ:NKTX – Get Rating) last announced its earnings results on Wednesday, November 9th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.04. As a group, research analysts predict that Nkarta will post -2.62 earnings per share for the current year.Institutional Trading of Nkarta
A number of institutional investors and hedge funds have recently bought and sold shares of NKTX. Parkwood LLC acquired a new stake in Nkarta during the 2nd quarter worth approximately $31,000. Quantbot Technologies LP increased its position in Nkarta by 39.1% during the 1st quarter. Quantbot Technologies LP now owns 3,200 shares of the company's stock worth $36,000 after purchasing an additional 900 shares in the last quarter. Denali Advisors LLC purchased a new position in Nkarta in the 2nd quarter worth approximately $38,000. Point72 Hong Kong Ltd purchased a new position in Nkarta in the 3rd quarter worth approximately $46,000. Finally, Federated Hermes Inc. boosted its holdings in Nkarta by 735.3% in the 1st quarter. Federated Hermes Inc. now owns 4,711 shares of the company's stock worth $54,000 after acquiring an additional 4,147 shares during the period. Institutional investors and hedge funds own 87.22% of the company's stock.
Nkarta Company Profile
(Get Rating)
Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.
Further Reading
- Get a free copy of the StockNews.com research report on Nkarta (NKTX)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- Analysts Like The Fit Of Skechers USA
- What Does Microsoft's Investment in ChatGBT Mean for MSFT Stock?
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.